[1] Kim B H, Park J W. Epidemiology of liver cancer in South Korea.Clin Mol Hepatol, 2017,24(1):1-9. [2] Ho M C, Hasegawa K, Chen X P, et al. Surgery for intermediate and advanced hepatocellular carcinoma: A consensus report from the 5th Asia-pacific primary liver cancer expert meeting (APPLE 2014). Liver Cancer, 2016, 5(4):245-256. [3] 张伟,陈刚,孙密密,等.经导管肝动脉化疗栓塞联合射频消融治疗原发性PLC患者临床疗效评价.实用肝脏病杂志,2017,20(4):472-476. [4] Shiraishi S, Moore K L. Knowledge-based prediction of three-dimensional dose distributions for external beam radiotherapy.Med Phys,2016,43(1):378-387. [5] Rades D, Bolm L, Schild S E, et al. Survival following palliative external-beam radiotherapy of locally advanced and metastatic liver cancer.Anticancer Res, 2017,37(1):203-210. [6] 中国抗癌协会PLC专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会原发性肝癌学组.原发性肝癌规范化诊治的专家共识.中华肝脏病杂志,2009,17(6):403-410. [7] 王巍伟,孙家耀,王征,等.质子重离子治疗靠近消化道肝癌的剂量学研究.中华放射肿瘤学杂志,2018,27(11):999-1003. [8] Nishino M, Jackman D H, Yeap B Y, et al. New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer:comparison with original RECIST and impact on assessment of tumor response to targeted therapy. Am J Roentgenol, 2010,195(3):221-228. [9] Hu B, Yang X R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.Clin Cancer Res, 2014,20(23):6212-6222. [10] Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration.Semin Radiat Oncol,2011,21(4):256-263. [11] Lyu N , Kong Y , Mu L ,et al. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial.Eur Radiol,2016,26(10):3492-3499. [12] Lee T Y , Lin C C , Chen C Y , et al. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.Medicine,2017,96(37):e7655-e7658. [13] Lee M W , Park S G , Woo H Y , et al. Three-dimensional conformal radiotherapy for portal vein tumor thrombosis in advanced hepatocellular carcinoma.Gastroenterology,2017,152(5):S1175-S1176. [14] Colbert L E, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.Adv Radiat Oncol, 2017,2(3):403-415. [15] Zhao J, Hu W, Cai G, et al. Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost.Med Phys, 2016,7(5):6345-6351. [16] Van Roozendaal L M , Schipper R J , Smit L H M , et al. Three-dimensional breast radiotherapy and the elective radiation dose at the sentinel lymph node site in breast cancer.Ann Surg Oncol,2015,22(12):3824-3830. [17] Xiong J , Chian S K , Li J , et al. Iodine-125 seed implantation for synchronous pancreatic metastases from hepatocellular carcinoma: A case report and literature review.Medicine,2017,96(46):e8726-e8731. [18] 牛焕章,肖全平,李东民,等.125I粒子植入联合肝动脉化疗栓塞治疗中晚期原发性肝癌的近期疗效.中华肝胆外科杂志,2017,23(11):776-781. [19] Zhang J, Wu N, Lian Z, et al. The combined antitumor effects of125I radioactive particle implantation and cytokine-induced killer cell therapy on xenograft hepatocellular carcinoma in a mouse model.Technol Cancer Res T,2017,16(6):1083-1091. [20] Yao M , Wang L , Leung P S C , et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review.Clin Rev Allerg Immu, 2018,54(2):282-294. |